Thermosensitive Injectable Dual Drug-Loaded Chitosan-Based Hydrogels for Treating Bacterial Endometritis
Source abstract
Abstract
Endometritis, a prevalent obstetric condition primarily caused by Escherichia coli ( E. coli) and Staphylococcus aureus ( S. aureus ), significantly threatens the reproductive performance of female animals. In this study, thermosensitive injectable chitosan (CS)/β-glycerophosphate (β-GP) hydrogels loaded with berberine (BBR) and carvacrol (CAR) were prepared for endometritis treatment. In vitro, BBR/CAR-CS/β-GP hydrogels exhibited rapid gelation within 5 min at 37 °C, excellent injectability, and more than 90% degradation within 30 days under enzymatic action. The dual drug-loaded system also exhibited controlled release of BBR and CAR and demonstrated the antimicrobial activity against E. coli and S. aureus . In vivo, uterine injection of BBR/CAR-CS/β-GP hydrogels alleviated infection-induced injuries and reduced the bacterial load in infected uterine tissues. In summary, these findings highlight the potential of BBR/CAR-CS/β-GP hydrogels as innovative carriers for drug delivery targeting endometritis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Reproductive System and Pregnancy · Endometriosis Research and Treatment · Gynecological conditions and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China
Funding
the Scholars Program of Northeast Agricultural University
References (56)
Show source-provided references
1. 10.1039/C9FO02963J10.1039/C9FO02963J ↗
2. 10.1016/j.theriogenology.2011.07.01710.1016/j.theriogenology.2011.07.017 ↗
3. 10.1095/biolreprod.109.07737010.1095/biolreprod.109.077370 ↗
4. 10.1128/spectrum.00811-2210.1128/spectrum.00811-22 ↗
5. 10.1039/C9FO00654K10.1039/C9FO00654K ↗
6. 10.1039/D2BM01586B10.1039/D2BM01586B ↗
7. 10.3205/id00004010.3205/id000040 ↗
8. 10.5187/jast.2022.e5910.5187/jast.2022.e59 ↗
9. 10.1007/s43032-023-01163-610.1007/s43032-023-01163-6 ↗
10. 10.1016/j.carbpol.2020.11681110.1016/j.carbpol.2020.116811 ↗
11. 10.1080/1061186X.2017.140055110.1080/1061186X.2017.1400551 ↗
12. 10.1016/j.ijpharm.2014.09.05810.1016/j.ijpharm.2014.09.058 ↗
13. 10.1016/j.cej.2021.13030210.1016/j.cej.2021.130302 ↗
14. 10.1016/j.ejps.2021.10604110.1016/j.ejps.2021.106041 ↗
15. 10.1016/j.ejps.2016.06.01410.1016/j.ejps.2016.06.014 ↗
16. 10.1016/j.carbpol.2017.02.00110.1016/j.carbpol.2017.02.001 ↗
17. 10.3389/fbioe.2021.65059810.3389/fbioe.2021.650598 ↗
18. 10.1111/jcmm.1817710.1111/jcmm.18177 ↗
19. 10.3389/fmicb.2020.0062110.3389/fmicb.2020.00621 ↗
20. 10.1159/00047941110.1159/000479411 ↗
21. 10.1080/10408398.2011.65345810.1080/10408398.2011.653458 ↗
22. 10.1002/ptr.610310.1002/ptr.6103 ↗
23. 10.1002/ptr.279810.1002/ptr.2798 ↗
24. 10.1016/j.carbpol.2022.11914510.1016/j.carbpol.2022.119145 ↗
25. 10.1016/j.jconrel.2020.06.01210.1016/j.jconrel.2020.06.012 ↗
26. 10.1002/app.4000610.1002/app.40006 ↗
27. 10.1016/j.ijbiomac.2018.10.01410.1016/j.ijbiomac.2018.10.014 ↗
28. 10.1016/j.msec.2019.02.02410.1016/j.msec.2019.02.024 ↗
29. 10.1016/j.carbpol.2023.12113810.1016/j.carbpol.2023.121138 ↗
30. 10.1016/j.foodhyd.2023.10945310.1016/j.foodhyd.2023.109453 ↗
31. 10.1016/j.carbpol.2023.12123510.1016/j.carbpol.2023.121235 ↗
32. 10.1021/acsami.7b0320810.1021/acsami.7b03208 ↗
33. 10.1002/advs.20230696410.1002/advs.202306964 ↗
34. 10.3390/ijms23221401310.3390/ijms232214013 ↗
35. 10.1007/s00253-020-10685-x10.1007/s00253-020-10685-x ↗
36. 10.1016/j.envpol.2020.11474810.1016/j.envpol.2020.114748 ↗
37. 10.1021/acs.jafc.3c0355210.1021/acs.jafc.3c03552 ↗
38. 10.1016/j.carbpol.2023.12126410.1016/j.carbpol.2023.121264 ↗
39. 10.1016/j.msec.2018.12.10910.1016/j.msec.2018.12.109 ↗
40. 10.1016/j.jiec.2016.12.02310.1016/j.jiec.2016.12.023 ↗
41. 10.3762/bjnano.13.5610.3762/bjnano.13.56 ↗
42. 10.3390/pharmaceutics1412263810.3390/pharmaceutics14122638 ↗
43. 10.1016/j.heliyon.2023.e1880410.1016/j.heliyon.2023.e18804 ↗
44. 10.1016/j.carbpol.2019.11551610.1016/j.carbpol.2019.115516 ↗
45. 10.1016/j.msec.2021.11232810.1016/j.msec.2021.112328 ↗
46. 10.1016/j.carbpol.2023.12146610.1016/j.carbpol.2023.121466 ↗
47. 10.1016/j.psj.2024.10365710.1016/j.psj.2024.103657 ↗
48. 10.1016/j.carbpol.2012.06.06910.1016/j.carbpol.2012.06.069 ↗
49. 10.1016/j.carbpol.2013.02.03110.1016/j.carbpol.2013.02.031 ↗
50. 10.3389/fphar.2021.64438710.3389/fphar.2021.644387 ↗
51. 10.1038/s41598-020-79713-010.1038/s41598-020-79713-0 ↗
52. 10.1016/j.micpath.2020.10454210.1016/j.micpath.2020.104542 ↗
53. 10.1002/bab.191710.1002/bab.1917 ↗
54. 10.1016/j.actbio.2019.01.00110.1016/j.actbio.2019.01.001 ↗
55. 10.1016/j.mtbio.2023.10087510.1016/j.mtbio.2023.100875 ↗
56. 10.1016/j.ijpharm.2021.12131510.1016/j.ijpharm.2021.121315 ↗